Multi-Dose Safety/Pharmacodynamic Study of SEL-212/SEL-037 in Subjects With Symptomatic Gout & Elevated Blood Uric Acid

PHASE2CompletedINTERVENTIONAL
Enrollment

152

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

December 31, 2018

Study Completion Date

January 31, 2019

Conditions
Gout ChronicHyperuricemia
Interventions
DRUG

SEL-212

SEL-212, biologic

DRUG

SEL-037

SEL-037, biologic

DRUG

SVP-rapamycin (SEL-110)

SVP-rapamycin, biologic

Trial Locations (13)

16635

Altoona Center for Clinical Research, Duncansville

27410

Triad Clinical Trials LLC, Greensboro

32713

Omega Research Consultants LLC, DeBary

32806

Compass Research LLC, Orlando

33765

Clinical Research of West Florida, Clearwater

40213

L-MARC, Louisville

45242

New Horizons Clinical Research, Cincinnati

83642

Advanced Clinical Research, Boise

84088

Advanced Clinical Research, West Jordan

92020

Tri West Research Associates LLC, El Cajon

92614

Irvine Center for Clinical Research Inc., Irvine

92801

Anaheim Clinical Trials, Anaheim

96814

East-West Medical Research Institute, Honolulu

All Listed Sponsors
lead

Selecta Biosciences, Inc.

INDUSTRY

NCT02959918 - Multi-Dose Safety/Pharmacodynamic Study of SEL-212/SEL-037 in Subjects With Symptomatic Gout & Elevated Blood Uric Acid | Biotech Hunter | Biotech Hunter